Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALLIPER trial of IMU-838 in progressive multiple sclerosis
2024-514617-35-00Phase 2Authorised
- Sponsor
- Immunic Therapeutics
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing IMU-838 with Placebo (2 arms). Primary endpoint: Annualized rate of percent brain volume change. Planned start Dec 2021; status: authorised.
02
Drugs
vidofludimus calcium
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2024-514617-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514617-35-00.